Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over ...

Researchers at Kumamoto University have discovered a monoclonal antibody capable of neutralizing a wide range of SARS-CoV-2 ...

KisoJi Biotechnology Inc., a company focused on the discovery and development of transformative antibody therapeutics, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ...

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap ...

The H5N1 bird flu outbreak in the U.S. has so far been shockingly mild. Researchers have some theories as to why.

Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV ... scientists have continued to ...

This interesting study presents valuable information on how human cytomegalovirus (HCMV) infection disrupts the activity of the TEAD1 transcription factor, leading to widespread chromatin alterations.

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

Rallybio (RLYB) announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and ...

Scientists have unveiled a new tool for studying the highly variable traits that allow malaria parasites to stick to red ...